Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer

What Was Tested

The paper reports a study of Goserelin, published as a randomized controlled trial.

Who Took Part

The abstract describes 1999, patients taking part.

The age groups tagged for this paper are adults and middle-aged adults, women only.

From 1990 to 1999, 1063 patients were randomized to receive (i) goserelin for 24 months (n = 346), (ii) six courses of 'classical' CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy (n = 360), or (iii) six courses of CMF plus 18 months goserelin (CMF→ goserelin; n = 357).

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Goserelin and who got the comparison, which limits bias.

The methods mention a period of 24 months.

Median follow-up was 12.1 years.

What Was Measured

The subject headings attached to it are Antineoplastic Agents, Hormonal, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant, Cyclophosphamide, Disease-Free Survival and Fluorouracil.

What This Means in Plain Language

The paper is a randomized study of Goserelin in 1999, patients over 24 months.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2011 (Annals of oncology : official journal of the European Society for Medical Oncology), a journal based in England.

More context: the Goserelin compound page, all human trials.